New Insights into Carnitine-acylcarnitine Translocase Deficiency from 23 Cases: Management Challenges and Potential Therapeutic Approaches
Overview
Authors
Affiliations
Carnitine acyl-carnitine translocase deficiency (CACTD) is a rare autosomal recessive disorder of mitochondrial long-chain fatty-acid transport. Most patients present in the first 2 days of life, with hypoketotic hypoglycaemia, hyperammonaemia, cardiomyopathy or arrhythmia, hepatomegaly and elevated liver enzymes. Multi-centre international retrospective chart review of clinical presentation, biochemistry, treatment modalities including diet, subsequent complications, and mode of death of all patients. Twenty-three patients from nine tertiary metabolic units were identified. Seven attenuated patients of Pakistani heritage, six of these homozygous c.82G>T, had later onset manifestations and long-term survival without chronic hyperammonemia. Of the 16 classical cases, 15 had cardiac involvement at presentation comprising cardiac arrhythmias (9/15), cardiac arrest (7/15), and cardiac hypertrophy (9/15). Where recorded, ammonia levels were elevated in all but one severe case (13/14 measured) and 14/16 had hypoglycaemia. Nine classical patients survived longer-term-most with feeding difficulties and cognitive delay. Hyperammonaemia appears refractory to ammonia scavenger treatment and carglumic acid, but responds well to high glucose delivery during acute metabolic crises. High-energy intake seems necessary to prevent decompensation. Anaplerosis utilising therapeutic d,l-3-hydroxybutyrate, Triheptanoin and increased protein intake, appeared to improve chronic hyperammonemia and metabolic stability where trialled in individual cases. CACTD is a rare disorder of fatty acid oxidation with a preponderance to severe cardiac dysfunction. Long-term survival is possible in classical early-onset cases with long-chain fat restriction, judicious use of glucose infusions, and medium chain triglyceride supplementation. Adjunctive therapies supporting anaplerosis may improve longer-term outcomes.
Drole Torkar A, Klinc A, Remec Z, Rankovic B, Bartolj K, Bertok S Int J Neonatal Screen. 2025; 11(1).
PMID: 39982343 PMC: 11843868. DOI: 10.3390/ijns11010009.
Emergency Management of Intoxication-Type Inherited Metabolic Disorders.
Tarr J, Morris A J Inherit Metab Dis. 2025; 48(2):e70007.
PMID: 39953653 PMC: 11828970. DOI: 10.1002/jimd.70007.
Hishida R, Ishiguro K, Yamanaka T, Toyokuni S, Matsui H Mol Genet Metab Rep. 2024; 41:101165.
PMID: 39650084 PMC: 11625244. DOI: 10.1016/j.ymgmr.2024.101165.
Carnitine-acylcarnitine translocase deficiency: a case report with autopsy.
Thunga C, Mitra S, Dayal D, Lal S Autops Case Rep. 2024; 14:e2024483.
PMID: 38628283 PMC: 11021025. DOI: 10.4322/acr.2024.483.
Portuguese Neonatal Screening Program: A Cohort Study of 18 Years Using MS/MS.
Goncalves M, Marcao A, Sousa C, Nogueira C, Fonseca H, Rocha H Int J Neonatal Screen. 2024; 10(1).
PMID: 38535129 PMC: 10971468. DOI: 10.3390/ijns10010025.